이윤빈 (서울대학교 의과대학)님 | 한빛사연구자 > 한빛사

서울대학교 의과대학

최종업데이트 2022.02.24.

A phase 1/2a trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma
- Clin. Cancer Res., 2023 Jul 17;CCR-23-0581 | https://doi.org/10.1158/1078-0432.CCR-23-0581
- 2023-07
- 의약학
- 한빛사논문
Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis
- Hepatology, First published: 31 January 2022 | https://doi.org/10.1002/hep.32380
- 2022-01
- 의약학
- 한빛사논문
Association of Metabolic Risk Factors With Risks of Cancer and All-Cause Mortality in Patients With Chronic Hepatitis B
- Hepatology, First published: 02 November 2020 | https://doi.org/10.1002/hep.31612
- 2020-11
- 의약학
- 한빛사논문
Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy
- Aliment. Pharmacol. Ther., Volume 46, Issue 9, November 2017, Pages 845-855 | https://doi.org/10.1111/apt.14275
- 2017-11
- 의약학
- 구.추천논문

연구자 ID

저자논문